Skip to main content
. Author manuscript; available in PMC: 2017 Apr 12.
Published in final edited form as: Pac Symp Biocomput. 2016;22:545–556. doi: 10.1142/9789813207813_0050

Table 4.

Genotyping Quality Control and Minor Allele Frequencies

Gene SNP Minor Allele Call Ratea Minor Allele Frequency (%)
Combined (n=2181) Whites (n=1928) Blacks (n=253)
VKORC1 rs9923231 T 99.79b 35.1 38.3 10.5
VKORC1 rs2359612 A 100 36.4 38.5 20.8
VKORC1 rs2884737 C 99.96 23.3 25.3 3.8
VKORC1 rs61162043 A 93.82 37.2 35.8 49.6
VKORC1 rs7200749 A 99.96 2.6 0.3 20.2
VKORC1 rs8050894 G 99.92 37.3 38.8 26.5
VKORC1 rs9934438 A 99.96 35.1 38.4 10.5
VKORC1 rs17886199 G 100 0.5 0 4.2
STX4 rs10871454 T 99.96 35.3 38.5 10.9
CYP2C9*2 rs1799853 T 99.79b 13.5 14.9 2.4
CYP2C9*3 rs1057910 C 99.95b 6.1 6.7 2.0
CYP2C9*5 rs28371686 G 100 0.2 0.05 1.6
CYP2C9*6 rs9332131 del 99.79 0.2 0 1.4
CYP2C9*8 rs7900194 A 100 0.9 0.03 7.3
CYP2C9*11 rs28371685 T 99.96 0.4 0.3 1.4
CYP4F2 rs2108622 T 100 28.2 30.4 11.3
GGCX rs11676382 G 99.96 8.8 9.7 2.6
GGCX rs12714145 T 100 42.1 41.6 45.8
CALU rs339097 G 99.83 1.6 0.2 12.3
CYP2C-cluster rs12777823 A 99.92 16.1 14.6 28.1
a

Call rates for completed genotyped population – not the final study population (as valid genotypes required for all but rs61162043);

b

Call rate for Taqman group only. ADME QC according to typical procedures.

HHS Vulnerability Disclosure